Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer (DAPROCA-1)

This study has been terminated.
(A consequence of the results of the ENTHUSE phase III study program)
Rigshospitalet, Denmark
Information provided by (Responsible Party):
Michael Borre, Aarhus University Hospital Identifier:
First received: October 22, 2009
Last updated: January 7, 2014
Last verified: July 2011
This is a prospective, open, one-arm, two-centre, Phase II clinical safety pilot-study. The trial is designed to gain initial safety and efficacy-related data on once-daily orally administered ZD4054 10 mg in prior chemotherapy treated patients with metastatic hormone-resistant prostate cancer.

Condition Intervention Phase
Prostate Cancer
Drug: ZD4054
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Phase II, Two-centre, 1-Arm Safety Study of Once-daily Orally Administered 10 mg ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Aarhus University Hospital:

Primary Outcome Measures:
  • To assess the safety and tolerability profile of ZD4054 after treatment with chemotherapy [ Time Frame: 2 years ]
  • Adverse events [ Time Frame: 2 years ]
  • Vital signs [ Time Frame: 2 years ]
  • Laboratory data [ Time Frame: 2 years ]
  • ECGs [ Time Frame: 2 years ]
  • Physical Exam [ Time Frame: 2 years ]
  • Death from any cause [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • To investigate the effect of ZD4054 on rate of rise of PSA [ Time Frame: 2 years ]
  • To investigate the effect of ZD4054 on prostate cancer related pain [ Time Frame: 2 years ]
  • To investigate the effect of ZD4054 on the plasma concentration of circulating tumour cells (CTC). [ Time Frame: 2 years ]

Enrollment: 24
Study Start Date: October 2009
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ZD4054
The study had only one arm: intervention
Drug: ZD4054
ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provision of informed consent
  2. Male, aged 18 years or older
  3. Histological or cytological confirmation of adenocarcinoma of the prostate
  4. Documented evidence of bone metastasis on bone scans.
  5. Surgically castrated or continuously medically castrated with serum testosterone less than 2.4 nmol/L (70 ng/dL).
  6. Previously (not inside 8 weeks) treated with at least two times 75 mg/m2 docetaxel.
  7. Biochemical progression of prostate cancer after chemotherapy, documented while the patient is castrate:

    o Biochemical progression is defined as at least 2 stepwise increases (≥1ng/mL) in PSA over a period of ≥1 month (values do not need to be consecutive but 2 values that have increased since the previous highest value are required) with at least 14 days between each measurement irrespective of assay or laboratory.

  8. Life expectancy of 3 months or more.

Exclusion Criteria:

  1. Use of potent CYP450 inducers (such as phenytoin, rifampicin, carbamazepine, phenobarbitone and St John's Wort) within 2 weeks of starting study treatment. Dexamethasone will be allowed if the investigator feels it is necessary but is encouraged to use a different form of steroid treatment wherever possible
  2. Have received investigational drug in another clinical study of anticancer therapy, within 4 weeks of starting study treatment
  3. Hypersensitivity to endothelin antagonists
  4. Neurological symptoms or signs consistent with acute or evolving spinal cord compression. If a patient has neurologic symptoms, an MRI must be performed that demonstrates no impending or actual spinal cord compression. Stable, previously treated patients are allowed
  5. History of past or current epilepsy, epilepsy syndrome, or other seizure disorder
  6. Stage II, III or IV cardiac failure (classified according to New York Heart Association (NYHA) classification) or myocardial infarction within 6 months prior to study entry
  7. QT interval corrected for heart rate e.g., by Bazett's correction >470 msec
  8. In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g., currently unstable or uncompensated respiratory, cardiac, hepatic or renal disease) or evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
  9. Hemoglobin (Hb) <5 mmol/L. Concomitant use of erythropoietin or blood transfusions is allowed
  10. Serum bilirubin >1.5 times the upper limit of normal (ULN). This will not apply to patients with Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology), who will be allowed in consultation with their physician
  11. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times the ULN or 5 times the ULN in the presence of liver metastasis
  12. Creatinine clearance of <50 mL/minute, determined using the Cockcroft-Gault equation or by 24-hour creatinine clearance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01000948

Dpt of Urology,Aarhus University Hospital
Aarhus, Denmark, 8200
Sponsors and Collaborators
Aarhus University Hospital
Rigshospitalet, Denmark
Study Chair: Michael Borre, MD Phd DMSc Dpt Urology Aarhus University Hospital - DAPROCA
  More Information

Responsible Party: Michael Borre, Professor, DMSci, PhD, Aarhus University Hospital Identifier: NCT01000948     History of Changes
Other Study ID Numbers: ISSIS40540005
Study First Received: October 22, 2009
Last Updated: January 7, 2014

Keywords provided by Aarhus University Hospital:
Prostate cancer
Castration resistant
Chemotherapy resistant
Endothelial receptor A inhibitor

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on April 27, 2017